Groundbreaking News in Lung Cancer Treatment: A Game-Changer for Patients? Kelun-Biotech has just announced a major breakthrough in the fight against non-small cell lung cancer (NSCLC). Their Phase III trial of sacituzumab tirumotecan (sac-TMT) combined with KEYTRUDA® (pembrolizumab) as a first-line treatment for PD-L1-positive NSCLC has hit its primary goal, showing a significant improvement in progression-free survival (PFS). But here's where it gets even more exciting: this is the first time a combination of an antibody-drug conjugate (ADC) and an immune checkpoint inhibitor has proven successful in a Phase III trial for first-line NSCLC treatment.
In simpler terms, this means patients with advanced lung cancer could soon have a new, potentially life-extending treatment option. The study, known as OptiTROP-Lung05, compared the sac-TMT and pembrolizumab combination to pembrolizumab alone in patients with PD-L1-positive locally advanced or metastatic NSCLC. The results? Not only did the combination therapy show a clear improvement in PFS, but it also hinted at better overall survival rates.
And this is the part most people miss: Sac-TMT isn’t just another experimental drug. It’s already approved in China for treating EGFR-mutant NSCLC in later stages, where it’s shown dual benefits in both PFS and overall survival. This makes it the first ADC to demonstrate such significant improvements compared to traditional chemotherapy. These findings have been published in top-tier journals like The New England Journal of Medicine and The BMJ, solidifying its credibility.
Currently, sac-TMT is being tested in ten registrational studies for lung cancer, including five in China and five global Phase III trials. The drug works by targeting TROP2, a protein found on the surface of tumor cells. Once attached, it delivers a potent payload that damages the tumor’s DNA, leading to cell death. What’s more, its bystander effect allows it to kill neighboring cancer cells, making it a powerful tool in the fight against cancer.
Controversy Alert: While the results are promising, some experts question whether combining ADCs with immunotherapy is the best approach for all patients. Could this lead to increased side effects or resistance? And how will this impact the already complex landscape of cancer treatment options? We’d love to hear your thoughts in the comments.
Kelun-Biotech has also licensed sac-TMT to MSD (Merck & Co.) for development and commercialization outside Greater China, expanding its global reach. To date, sac-TMT has been approved in China for three indications, including triple-negative breast cancer (TNBC) and EGFR-mutant NSCLC, making it the first TROP2 ADC drug approved for lung cancer globally.
Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, is dedicated to developing innovative biological and small molecule drugs for major diseases like solid tumors, autoimmune disorders, and metabolic conditions. With over 30 ongoing projects, including 4 approved drugs and multiple clinical-stage candidates, they’re positioning themselves as a global leader in innovative therapies.
Thought-Provoking Question: As sac-TMT continues to show promise, how will it reshape the future of cancer treatment? Will it become the new standard of care, or will it remain a specialized option for certain patients? Share your insights below—we’re eager to hear your perspective!
